DailyIQ
Last updated2 minutes ago

AMGN·Amgen Inc.

$412.98
-4.59 (-1.10%)
Overnight$412.84-0.14 (-0.03%)
High
$421.97
Open
$420.34
Market Cap
224.29B
52W High
$447.03
Low
$411.04
P. Close
$412.98
P/E
25.65
52W Low
$287.25
Fwd P/E
16.85
DailyIQ Est.
$398.86
Inst. Ownership
43.0%
Short Interest
2.58%
Days to Cover
4.1
Div. Yield
2.41%
Next Ex-Div
~Nov 20
Div. Growth
13+ yrs
Technical Score (1D)
64
BULLISH
News Sentiment
54
MIXED
On Oct 13, Goldman Sachs raised its price target for Amgen from $450 to $475, citing an improved outlook for the company. The same day, Guggenheim analyst Vamil Divan lowered Amgen’s price target from $388 to $378 while keeping a neutral rating, noting modest headwinds in the oncology pipeline and competitive pressures. Both adjustments were reported on Oct 13, reflecting differing views on the company’s near‑term earnings prospects. The Goldman Sachs upgrade suggested a more optimistic view of Amgen’s prospects, whereas Guggenheim’s downgrade signaled a cautious assessment of the company’s valuation relative to peers. These moves were highlighted as potentially influencing investor sentiment and trading activity.
LOW TARGET
$225 -45.5%
3 analysts
MEAN TARGET
$394 -4.6%
28 analysts
HIGH TARGET
$500 +21.1%
12 analysts
PRICE RANGE
$225.00 - $500.00
SB / B / H / S / SS
6/14/20/2/1
DAILYIQ EST.
$398.86 (-3.4%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United States
Website
Symbol
AMGN
Description
Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and delivery of human therapeutics. The company's core value proposition lies in its diverse portfolio of innovative medicines designed to treat a wide range of serious illnesses. Key therapeutic areas include immunology, oncology, cardiovascular disease, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. Amgen distributes its products through healthcare providers, pharmacies, and direct-to-consumer channels, establishing a broad market reach. Strategic collaborations with other pharmaceutical companies, such as AstraZeneca and Novartis, further enhance its product pipeline and market presence, solidifying its competitive position in the biotechnology landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
10,112 shares
$4.1M
Khosla RachnaSVP, Business Development
Option Exercise1,252 shares2026-08-13
Khosla RachnaSVP, Business Development
Sell1,252 shares2026-08-13
Khosla RachnaSVP, Business Development
Option Exercise1,252 shares2026-08-13
Khosla RachnaSVP, Business Development
Sell2,000 shares2026-08-11
Busch Matthew C.VP, Finance & CAO
Award/Grant730 shares2026-08-07
68/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.2%
Net Margin
21.0%
Revenue CAGR
5.2%
Current Ratio
1.14x
Debt / Equity
6.31x
Return on Equity
89.1%
Earnings Summary
Amgen Inc. is a global biotechnology firm that discovers, develops, manufactures, and delivers human therapeutics across immunology, oncology, cardiovascular disease, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. The company operates within the broader healthcare sector, specifically the drug manufacturers‑general industry, and relies on a diversified portfolio and strategic collaborations to sustain its competitive position. In the most recent two quarters, Amgen reported Q4 2025 revenue of $9.866 billion, up 2.1% from Q4 2024’s $9.086 billion, while Q1 2026 revenue rose modestly to $8.618 billion from Q1 2025’s $8.149 billion, reflecting a slight deceleration in top‑line growth. EPS in Q4 2025 was $5.29, beating the $4.83 estimate, and Q1 2026 EPS was $5.15 versus a $4.77 estimate, indicating consistent earnings beats in both quarters. The company’s EPS growth accelerated from $4.90 in Q1 2025 to $6.02 in Q2 2025, then settled at $5.64 in Q3 2025, showing a pattern of strong profitability that has generally outpaced revenue growth. Historically, Amgen has maintained a YoY revenue growth trajectory of roughly 5–6% over the past four quarters, with EPS consistently beating analyst expectations in 3 of the last 4 quarters, underscoring a robust earnings performance even when revenue growth moderates. Recent news highlights include Goldman Sachs raising its price target to $475 on Oct 13 and UBS lifting its target to $470 on Oct 9, both reflecting heightened confidence in Amgen’s earnings outlook and product pipeline, particularly the KRAS inhibitor LUMAKRAS and the Arboretum precision‑medicine platform.

EPS

EstBeatMiss
$4.54$5.03$5.53$6.02$6.52Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.76 - -
Q2'26$5.73$6.29+9.8%
Q1'26$4.77$5.15+8.0%
Q4'25$4.83$5.29+9.6%
Q3'25$5.01$5.64+12.5%
Q2'25$5.28$6.02+14.1%

Revenue

EstBeatMiss
$8.3B$8.9B$9.4B$10.0B$10.5BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$10.2B - -
Q2'26$9.6B$10.1B+4.6%
Q1'26$8.6B$8.6B+0.5%
Q4'25$9.7B$9.9B+2.1%
Q3'25 - $9.6B -
Q2'25 - $9.2B -

Market Data

AMGN Stock Snapshot

NEUTRAL64/100
$412.84−$0.14 (0.0%)
Market cap
224.29B
P/E ratio
25.6
Day range
$411.04 – $421.97
News sentiment
54/100 · Neutral
Analyst target
$393.91 (-4.6%)
Consensus
Hold · 43 analysts
52-week range+43.7% off low · -7.6% from high
$287.25$447.03
Price $412.84 DailyIQ Est. $398.86

Amgen Inc. is consolidating: price is in the upper part of its 52-week range without a decisive push either way. A stock this widely held moves on consensus revisions more than on individual catalysts.

Reverse DCF

What growth is priced into AMGN?

RICH

At today's price, Amgen Inc. needs to grow free cash flow about 14.1% a year for the next 10 years to justify its valuation at a 7.55% cost of capital. Over its actual history it has compounded free cash flow at 4.3% a year, so the market is asking for 9.8 percentage points above its own delivered rate. On that basis AMGN looks priced above what its own growth record supports.

Implied FCF growth
14.1%
Historical FCF CAGR
4.3%
Growth gap
+9.8 pts
Verdict
RICH
Discount rate (WACC)
7.55%
Beta
0.62

Behaviour On Record

What AMGN's own history says about today's numbers

Realized volatility (21d)
27.7% 74th pct
Below its peak
-6.6%
vs 200-day average
+13.4%
Up days (1y)
52%

Amgen Inc. is currently running 27.7% annualised volatility over the last 21 sessions. Measured against AMGN's own 13 years of daily returns rather than a market-wide average, that is the 74th percentile — a little above its own norm, against a typical reading of 22.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

AMGN is trading -6.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -26.3% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +13.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 88th percentile — a wider gap than this stock usually carries. Over the past year AMGN closed higher on 52% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, AMGN finished the month higher 5 of 13 times, with a median return of -0.7% and an average of +0.8%. Its strongest month historically has been July at +3.9% on average, its weakest September at -1.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: AMGN has opened more than 2% away from the prior close in 44 of 3,264 sessions (1.3% of the time), with the largest gaps running +5.4% and -9.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, AMGN moved an average of 5.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +4.9% and a largest of +6.9%.

All figures computed from 3,265 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against AMGN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of AMGN's sector?

Amgen Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Options Market

What is the options market pricing for AMGN?

CallsPuts

For Amgen Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.50), with at-the-money implied volatility around 3.1%. The options market is pricing roughly a ±0.2% move by that expiry — a range of about $417.03–$418.97.

Put/call ratio (2026-10-16)
0.50
ATM implied volatility
3.1%
Total open interest
3
Expected move by 2026-10-16
±0.2% ($417.03–$418.97)

Analyst Rating Changes

Are analysts turning bullish or bearish on AMGN?

Guggenheim most recently reiterated its rating on Amgen Inc. to Neutral on Oct 13, 2026 with a price target of $378 (from $388). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.

Latest action
Guggenheim — Neutral
90-day upgrades
0
90-day downgrades
2
Net rating momentum
-2
DateFirmActionRatingPrice target
Oct 13, 2026GuggenheimMaintainedNeutral$388 → $378
Oct 12, 2026BMO CapitalMaintainedMarket Perform$450 → $415
Oct 12, 2026Wells FargoMaintainedEqual-Weight$435 → $430
Oct 9, 2026UBSMaintainedBuy$430 → $470
Oct 8, 2026RBC CapitalMaintainedOutperform$400 → $430
Oct 8, 2026Cantor FitzgeraldMaintainedNeutral$400 → $440
Oct 7, 2026Truist SecuritiesMaintainedHold$362 → $380
Oct 7, 2026Morgan StanleyMaintainedEqual-Weight$362 → $359
Sep 29, 2026ScotiabankMaintainedSector Outperform$450 → $500
Sep 10, 2026HSBCDowngradeBuy → Hold$445 → $425
Sep 8, 2026BMO CapitalDowngradeOutperform → Market Perform$450
Sep 8, 2026Cantor FitzgeraldReiteratedNeutral$400

Peers & ETF holders

AMGN peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

54/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Goldman Sachs increased its price target for Amgen from $450 to $475. The upgrade reflects a more optimistic view of the company's prospects. The move may influence investor sentiment and trading activity.
What did this article say?
Guggenheim analyst Vamil Divan downgraded Amgen’s price target from $388 to $378 while keeping a neutral rating. The adjustment reflects a reassessment of the company’s near‑term earnings outlook. The firm cited modest headwinds in the oncology pipeline and competitive pressures as reasons for the lower target. No immediate impact on guidance or strategic direction was noted. The move signals a cautious view of Amgen’s valuation relative to peers.
What did this article say?
On Oct 12, BofA Securities projected that Amgen's Q3 results would reflect continued commercial momentum. The forecast implied that sales and revenue growth would remain solid. This outlook supports a mild positive view of the company's performance.
What did this article say?
Amgen’s shares closed at $407.44, prompting analysis of whether the price reflects the company’s cash‑flow prospects. The article highlights the company’s KRAS inhibitor LUMAKRAS and its precision‑medicine platform Arboretum as key drivers that could boost future treatment adoption and cash generation. It argues that the current valuation may be undervalued by up to 40% if the underlying cash flows can support the price, suggesting a bullish view for investors.
What did this article say?
Amgen (AMGN) closed at $414.87 on October 9, up 1.82% from the previous day, outperforming the S&P 500’s 0.6% gain. The biotech firm’s share price has risen 6.53% over the past month, leading the medical sector despite broader market weakness. Analysts anticipate earnings of $5.70 per share and revenue of $9.92 billion for the quarter, modest year‑over‑year growth. Investors are watching the upcoming earnings release for confirmation of the company’s performance trajectory.
What did this article say?
The article identifies Amgen (AMGN) as one of two pharmaceutical stocks recommended for investors anticipating a market downturn by the end of 2027. It argues that drugmakers like Amgen possess diversified portfolios and chronic disease treatments that can sustain performance during recessions. The recommendation is based on analysts’ belief that Amgen’s business model can weather economic stress, positioning it as a defensive play. No specific financial metrics or guidance changes are disclosed, but the endorsement suggests a positive outlook for the company in a downturn scenario.
What did this article say?
UBS increased its price target for Amgen from $430 to $470 while keeping a buy recommendation. The adjustment reflects confidence in the company’s earnings outlook and product pipeline. The new target aligns with a broader positive view of Amgen’s valuation relative to peers. This move may support investor sentiment and could influence short‑term trading activity.
What did this article say?
UBS analyst Michael Yee kept a Buy rating on Amgen and increased the price target from $430 to $470. The upgrade reflects confidence in the company’s pipeline and earnings outlook. The move signals a positive market view but does not indicate a transformative shift in fundamentals.
What did this article say?
RBC lifted its price target for Amgen from $400 to $430 while keeping an outperform rating. The brokerage noted Amgen’s average analyst rating remains hold, with a mean target of $401.75. The upgrade reflects confidence in the company’s pipeline and market positioning. This adjustment signals a positive outlook for Amgen’s valuation prospects.
What did this article say?
RBC Capital analyst Luca Issi maintained an Outperform rating for Amgen and increased the price target from $400 to $430. The upgrade reflected confidence in the company’s pipeline and recent earnings performance. The move signals a positive outlook for Amgen’s valuation and growth prospects.

Technical Analysis

Real-time indicators across multiple timeframes

64
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $82.21B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy54,838,82610.09%$17.95B2026-01-29
BlackRock, Inc.▲ Buy49,362,0169.09%$17.87B2026-08-07
Capital World Investors▼ Sell29,075,3295.35%$10.53B2026-08-12
Invesco Ltd.▲ Buy16,320,4463.00%$5.91B2026-08-14
Geode Capital Management, LLC▲ Buy15,696,0682.89%$5.67B2026-08-12
Morgan Stanley▼ Sell13,653,6922.51%$4.94B2026-08-13
Wells Fargo & Company▲ Buy7,235,4621.33%$2.62B2026-08-14
Capital Research Global Investors▼ Sell6,272,6251.15%$2.27B2026-08-12
Northern Trust Corp▼ Sell6,200,9941.14%$2.25B2026-08-13
Norges Bank▼ Sell5,625,5841.04%$2.04B2026-08-12
Bank of America Corp▼ Sell5,058,8300.93%$1.83B2026-08-14
Goldman Sachs Group Inc▼ Sell4,130,7320.76%$1.50B2026-08-14
JPMorgan Chase & Co▼ Sell3,588,4840.66%$1.29B2026-08-12
FMR LLC (Fidelity)▼ Sell3,491,8220.64%$1.26B2026-08-13
Wellington Management Group LLP▲ Buy2,742,2710.50%$993.03M2026-08-14
Fisher Asset Management, LLC▲ Buy1,589,5540.29%$575.61M2026-08-04
D. E. Shaw & Co., Inc.▲ Buy1,290,2170.24%$467.21M2026-08-14
Two Sigma Investments, LP▲ Buy1,128,6810.21%$408.72M2026-08-14
Janus Henderson Group plc▼ Sell1,107,1590.20%$389.51M2026-05-18
Citigroup Inc▲ Buy1,020,8690.19%$369.68M2026-08-03
Citadel Advisors LLC▲ Buy703,9840.13%$254.93M2026-09-02
Neuberger Berman Group LLC▲ Buy646,7980.12%$234.17M2026-08-13
Prudential Financial Inc▲ Buy578,4740.11%$209.48M2026-08-12
AllianceBernstein L.P.▼ Sell587,2700.11%$206.63M2026-08-14
Adage Capital Partners GP, L.L.C.▲ Buy471,8330.09%$170.86M2026-08-14
Q2 2026 flow:13.31M sh bought ($4.82B)8.22M sh sold ($2.97B)net +5.09M sh (+$1.85B)
Congressional Trading Activity
25 disclosed trades · ~$371.5K est. traded value · 13 buys, 12 sells
MemberChamberStateTypeAmountTradedFiled
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-09-222026-10-01
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-08-262026-09-05
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2026-08-122026-09-02
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-06-052026-06-12
Maria Elvira SalazarHouseFL27▼ Sell$15K - $50K2026-04-172026-05-08
Alan ArmstrongSenateOK▼ Sell$15K - $50K2026-03-272026-07-21
Maria Elvira SalazarHouseFL27▲ Buy$15K - $50K2026-03-242026-04-21
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-02-262026-03-06
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-01-292026-02-02
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-01-162026-02-02
David J. TaylorHouseOH02▼ Sell$1K - $15K2025-12-032025-12-05
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-10-242025-10-28
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-09-252025-10-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-09-112025-09-27
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2025-09-042025-10-03
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-242025-08-13
Cliff BentzHouseOR02▲ Buy$1K - $15K2025-06-062025-07-09
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-142025-05-19
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-052025-05-06
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-04-162025-05-09
Tommy TubervilleSenateAL▼ Sell$15K - $50K2025-04-152026-08-05
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-112025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-02-242025-03-09